KIYATEC and AACR Joint Abstract at AACR Highlights Use of KIYA-PREDICT™ Drug Response Platform in ACC
Retrieved on:
Monday, April 4, 2022
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Company, Drug development, PDX, Life, ACC, LinkedIn, Non-small-cell lung carcinoma, Diagnosis, Adenoid cystic carcinoma, Microfluidics, Culture, Primary tumor, Liver, Breast, Research, Head, Adenoid, American Association, Ernest, Neoplasm, Cancer, Radiation, Statistics, Patient, Poster, Association, Annual general meeting, Twitter, Â, Brain, Facebook, Disease, Medical imaging, ADENOID CYSTIC CARCINOMA, THE ADENOID CYSTIC CARCINOMA RESEARCH FOUNDATION, KIYATEC, Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, ADENOID CYSTIC CARCINOMA, THE ADENOID CYSTIC CARCINOMA RESEARCH FOUNDATION, KIYATEC
The abstract, entitled Ex vivo 3D culture of adenoid cystic carcinoma PDX models recapitulate disease biomarkers and predict drug response, evaluates drug response using KIYATECs validated 3D-XPDX adenoid cystic carcinoma (ACC) model based on the KIYA-PREDICT drug response platform.
Key Points:
- The abstract, entitled Ex vivo 3D culture of adenoid cystic carcinoma PDX models recapitulate disease biomarkers and predict drug response, evaluates drug response using KIYATECs validated 3D-XPDX adenoid cystic carcinoma (ACC) model based on the KIYA-PREDICT drug response platform.
- KIYATEC Chief Executive Officer Matt Gevaert, Ph.D., said, We are honored to work with ACCRF for patients with this rare condition.
- Our collaboration represents the mission of KIYATEC to disrupt and inform cancer treatment options by accurately predicting therapeutic tumor response.
- Jeff Kaufman, Executive Director of ACCRF, said, It has been a pleasure to partner with KIYATEC to develop ex vivo ACC models for drug development and screening.